BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Bordeaux Neurocampus - ECPv4.9.10//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Bordeaux Neurocampus
X-ORIGINAL-URL:https://www.bordeaux-neurocampus.fr/en/
X-WR-CALDESC:Events for Bordeaux Neurocampus
BEGIN:VTIMEZONE
TZID:Europe/Paris
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20230326T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20231029T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20240331T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20241027T010000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230916
DTEND;VALUE=DATE:20240617
DTSTAMP:20260601T122104
CREATED:20230831T131841Z
LAST-MODIFIED:20240529T183442Z
UID:162245-1694822400-1718582399@www.bordeaux-neurocampus.fr
SUMMARY:Exposition : Cervorama
DESCRIPTION:Agitez vos neurones ! \nA travers cette exposition\, Cap Sciences propose aux visiteurs de découvrir le cerveau sous toutes ses formes lors d’une visite ponctuée de manipulations\, de jeux et d’expériences… Ils pourront notamment explorer les mondes des cerveaux de l’escargot\, l’abeille\, le singe et l’homme\, tester leur mémoire dans le “cognitilab”\, découvrir leur cerveau en 3D grâce au cervomaton ou encore analyser les capacités des animaux ! \nUne exposition conçue et réalisée par Cap Sciences en partenariat avec Bordeaux Neurocampus\n \nEn savoir plus\nSite web : https://www.cap-sciences.net/au-programme/exposition/grand-public/cervorama/ \n
URL:https://www.bordeaux-neurocampus.fr/en/event/exposition-cervorama/
CATEGORIES:Events for all,not-calendar,pour tous homepage,Semaine du cerveau 2024
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Paris:20231204T140000
DTEND;TZID=Europe/Paris:20231204T140000
DTSTAMP:20260601T122104
CREATED:20231110T093721Z
LAST-MODIFIED:20231123T154011Z
UID:164278-1701698400-1701698400@www.bordeaux-neurocampus.fr
SUMMARY:Thesis defense - Pierre-Louis Raux
DESCRIPTION:Venue: Neurocentre Magendie \n\nPierre-Louis Raux\nTeam: Physiopathology and therapeutic approaches of stress-related diseases\nNeurocentre Magendie\n \nThesis supervisor:  Monique Vallée \nTitle\nDevelopment and characterization of the CB1-E134G transgenic mouse model to study the role of endogenous pregnenolone in modulating the endocannabinoid system \nAbstract\nThe endocannabinoid system (ECS) is a complex neuromodulatory network that has attracted tremendous research interest over the past 50 years. The vast majority of our knowledge of ECS-mediated signaling is associated with the type 1 cannabinoid receptor (CB1R)\, a seven-transmembrane domain G-protein coupled receptor. CB1R is expressed in various organs and tissues\, with the highest levels found in the brain\, where it is the most abundant metabotropic receptor in mammals and is intimately involved in the regulation of a plethora of biological functions. Because CB1R controls such a broad range of physiological processes\, dysregulation of CB1-mediated signaling has been implicated in the pathogenesis of many central and peripheral disorders. Thus\, CB1R represents an exciting therapeutic target for the development of pharmacotherapies in the context of neuropsychiatric and metabolic diseases. From this perspective\, the discovery of endogenous regulatory mechanisms to prevent an imbalance in CB1R activity represents promising therapeutic strategies to restore the CB1R-associated homeostatic load. In particular\, the steroid pregnenolone (PREG) has been identified as an endogenous CB1 negative allosteric modulator with neuroprotective effects. Interestingly\, CB1 overactivation by the exogenous CB1 agonist Δ9- tetrahydrocannabinol (THC)\, the primary psychoactive component of Cannabis sativa\, has been shown to upregulate central PREG levels\, establishing an endogenous negative feedback loop between the steroid and the CB1R. Indeed\, PREG is able to bind to the TMH1/TMH8/Hx8 region of the CB1R and selectively inhibit CB1-mediated signaling pathways to protect against the acute and toxic effects of THC. However\, our current knowledge of the interaction between PREG and CB1R remains elusive\, and the limited pharmacological tools available are insufficient to identify novel roles for PREG in modulating CB1-mediated signaling and functions. To further explore this topic\, we report the development and characterization of a novel transgenic mouse line carrying a missense point mutation in the CB1-encoding gene (Cnr1)\, resulting in the amino acid substitution E134G\, aimed at disrupting the PREG allosteric binding site on CB1. The general objectives of this work are to describe the phenotypes of male and female CB1-E134G mice at baseline\, under experimental conditions known to induce endogenous CB1R activation\, and in response to exogenous cannabinoid administration. Analyses show little to no changes in behavior of mutant CB1-E134G mice compared to their wild-type (WT) littermates\, at baseline and after endogenous CB1 activation\, suggesting that endogenous PREG does not regulate this CB1 activity. However\, CB1 protein was found to be drastically downregulated in the brain of naive CB1-E134G mutants\, suggesting a compensatory mechanism to prevent CB1R activation overload and a role for PREG in CB1R dynamics in vivo. In addition\, CB1-E134G mice exhibited enhanced efficacy of exogenous cannabinoids at the behavioral\, somatic and neurochemical levels compared to WT mice. Interestingly\, PREG was found to preferentially regulate striatonigral mitochondria-associated CB1R over plasma membrane-associated CB1R involved in cannabinoid-mediated locomotor effects and antinociception\, respectively. Collectively\, these data confirm that PREG represents a defense mechanism against CB1 overactivation and suggest that this regulatory loop may involve specific intracellular subsets of receptors to maintain homeostasis. Furthermore\, it can be hypothesized that PREG represents a molecular switch to bias the action of cannabinoids towards therapeutically relevant analgesia by inhibiting motor side effects\, suggesting the therapeutic potential of PREG in cannabis use disorders. Finally\, future use of this model may provide new opportunities to elucidate the mechanism of action of PREG as a CB1 negative allosteric modulator and new therapeutic prospects. \nJury\nFrancis CHAOULOFF\, DR INSERM U1215\, Université de Bordeaux ; Président \nElena MARTIN-GARCIA\, Professeur\, Université Pompeu Fabra ; Rapportrice \nGiuseppe GANGAROSSA\, Professeur\, Université Paris Cité ; Rapporteur \nYvette AKWA\, Chargée de recherche\, INSERM 1195 ; Examinatrice \nRoberto FRAU\, Prof Associate\, Université de Cagliari ; Examinateur \nMonique VALLÉE\, CR CNRS\, Université de Bordeaux ; Directrice de thèse \n  \n
URL:https://www.bordeaux-neurocampus.fr/en/event/thesis-defense-pierre-louis-raux/
CATEGORIES:Thesis
END:VEVENT
END:VCALENDAR